

Gibson Dunn Advises Mentari Therapeutics on Merger With InMed Pharmaceuticals and Concurrent \$290 Million Private Placement

Firm News | May 21, 2026

Gibson Dunn is advising Mentari Therapeutics, Inc. on its merger with InMed Pharmaceuticals, Inc. and concurrent \$290 million private placement.

The Gibson Dunn corporate team includes partners Ryan Murr and Branden Berns and associate Evan Shepherd.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Evan Shepherd](#)